Aurobindo Pharma arm gets USFDA nod for Carboprost Tromethamine Injection

• Failure of expulsion of the fetus during the course of treatment by another method.

• Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity.

• Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus.

• Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.

Carboprost Tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of Carboprost Tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, Carboprost Tromethamine injection used in this manner has resulted in the cessation of lifethreatening bleeding and the avoidance of emergency surgical intervention.

Read also: Cipla, Aurobindo, Viatris in licensing pact with MPP to produce generic versions of ViiV Healthcare HIV drug